OS Therapies (NYSE:OSTX) Shares Up 5.1% – Here’s Why

OS Therapies Inc (NYSE:OSTX) shares rose 5.1% on Friday . The company traded as high as $2.06 and last traded at $1.95. Approximately 20,692 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 133,760 shares. The stock had previously closed at $1.86.

Analysts Set New Price Targets

A number of research analysts have recently commented on OSTX shares. EF Hutton Acquisition Co. I upgraded OS Therapies to a “strong-buy” rating in a research note on Tuesday, September 3rd. Brookline Capital Management upgraded shares of OS Therapies to a “strong-buy” rating in a research report on Thursday, August 22nd.

OS Therapies Trading Up 5.1 %

The company’s 50-day simple moving average is $2.84.

Hedge Funds Weigh In On OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC acquired a new stake in shares of OS Therapies Inc (NYSE:OSTX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 10,045 shares of the company’s stock, valued at approximately $28,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.